
    
      This is a single center prospective, randomized, placebo-controlled trial in overweight/obese
      patients with insulin treated uncontrolled type 2 diabetes

      Eligible subjects willing to participate in the study will be randomized to one of 3
      treatment groups:

      Group 1: Insulin titration + behavioral therapy Basal insulin titration upto 12 weeks with 2
      U increment every 3 days (Fasting glucose goal <110) based on self-monitored blood glucose.

      After 12 weeks, patients with HbA1c >8% will switch to a basal bolus regimen.

      Group 2: Exenatide-LAR 2mg q week x 24 weeks + Dapagliflozin placebo x 52 weeks + titrated
      basal insulin +behavioral therapy.

      Group 3: Exenatide-LAR 2mg q week x 24 weeks plus Dapagliflozin 5mg QD x 2 weeks followed by
      10mg QD x22 weeks +titrated basal insulin + behavioral therapy.

      Behavioral therapy will be delivered by registered dietitians and will include the BMIQ
      program -a web based medical weight loss program.
    
  